VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands

NCT00440765 · clinicaltrials.gov ↗

COMPLETED

Status

331

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Hematological Neoplasms

Interventions

DRUG: bortezomib

Sponsor

Janssen-Cilag B.V.